NEWS
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
Autonomix Medical (NASDAQ: AMIX) announced the approval of a protocol amendment by the Ethics Committee for its ongoing proof-of-concept human clinical trial. The trial evaluates the safety and efficacy of delivering transvascular energy to ablate nerves and mitigate pain in pancreatic cancer patients. Following the treatment of the first five 'lead-in' patients, the protocol was amended to gather additional data on tumor encroachment and other bio-measurements, and to refine inclusion criteria based on patient-reported pain levels. Autonomix plans to release topline results from the lead-in patients soon and aims to complete trial enrollment by year-end. The company's catheter-based technology seeks to offer a targeted, effective alternative to current pain management methods.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1070Followers
68Following
7361Visitors
Follow